(RARE) Ultragenyx Pharmaceutical Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(RARE) Ultragenyx Pharmaceutical Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Ultragenyx Pharmaceutical Inc. BCG Matrix helps you see how the company’s products or business units are positioned across the four classic quadrants: Stars, Cash Cows, Question Marks, and Dogs. What you see on this page is a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Crysvita $1B+ sales, 2 indications
Crysvita is Ultragenyx’s main cash engine, with 2025 net sales above $1.0 billion and leadership in both X-linked hypophosphatemia and tumor-induced osteomalacia. It has the clearest global share in the franchise, and label support plus steady demand kept growth intact into 2026. In a BCG view, this is a Star: high share, high growth, and still the core value driver.
Crysvita XLH, pediatric and adult use
Crysvita is Ultragenyx Pharmaceutical Inc.'s core XLH brand, with use across pediatric and adult patients driving recurring chronic demand. In 2025, that broad patient base kept the franchise in a leadership spot, supported by ongoing treatment rather than one-time use. That mix of market strength and repeat uptake fits a Star profile.
Crysvita TIO, first FGF23 antibody
Tumor-induced osteomalacia is ultra-rare, but Crysvita, the first FGF23 antibody, remains the key targeted therapy. In Ultragenyx Pharmaceutical Inc.'s 2025 mix, it kept Star status because first-mover use and strong clinical demand support share even in a tiny niche. The BCG case is scale-light, but pricing power stays high.
Crysvita global rollout, multi-region access
Crysvita’s global rollout has moved Ultragenyx Pharmaceutical Inc. beyond a U.S.-only base, with approvals and reimbursement across Europe, Japan, Canada, and other markets. As access widens, the brand can keep adding patients and volume, which fits a Star: high share in a high-growth rare-disease market. In 2025, the franchise still benefited from new coverage wins and broader payer support.
- Multi-region access expands patient reach.
- Reimbursement supports volume growth.
- High share plus high growth fits Star status.
Crysvita cash generation, company funding source
Crysvita is Ultragenyx Pharmaceutical Inc.’s cash engine: in 2025 it still supplied most commercial revenue and funded pipeline work and launch spend. The franchise is the portfolio anchor, and its annual sales have been above $1.0 billion, giving Ultragenyx the cash it needs to run trials without relying only on outside funding.
- Crysvita funds most commercial cash flow
- Supports trials and new launches
- Anchor asset in Ultragenyx’s portfolio
Crysvita Tops $1B, Leading Ultragenyx’s Rare-Disease Growth
Crysvita is Ultragenyx Pharmaceutical Inc.'s Star asset: 2025 net sales topped $1.0 billion, and the brand kept leadership in XLH and TIO across key global markets. Strong reimbursement and broad chronic use support high share in a still-growing rare-disease niche.
| Asset | 2025 net sales | BCG view |
|---|---|---|
| Crysvita | Above $1.0B | Star |
What is included in the product
Detailed Word Document
Ultragenyx BCG Matrix maps its rare-disease portfolio into Stars, Cash Cows, Question Marks, and Dogs to guide invest/hold/divest decisions.
Editable Excel File
Quick BCG snapshot for Ultragenyx Pharmaceutical Inc. to spot strengths, gaps, and priorities fast.
Reference Sources
Lists credible sources behind Ultragenyx Pharmaceutical Inc. insights, helping users verify assumptions fast and make better-informed decisions.
Cash Cows
Mepsevii tens of millions in sales, 1 disease
Mepsevii is Ultragenyx Pharmaceutical Inc.'s enzyme replacement therapy for MPS VII, an ultra-rare disease estimated at fewer than 1 in 1,000,000 births. With one approved indication and a tiny patient pool, growth is capped, but annual sales still land in the tens of millions, making it a steady cash cow. Limited competition and chronic use support stable, niche revenue.
Mepsevii long-running approval, recurring treatment
Mepsevii has been commercialized since 2017 and treats mucopolysaccharidosis VII, a disease affecting fewer than 1 in 1,000,000 births. It is given every 2 weeks, so revenue comes from repeated chronic use rather than rapid new-patient growth. That steady, low-volume demand fits cash-cow behavior: mature brand, small market, recurring treatment. In Ultragenyx’s 2025 reporting, Mepsevii remained a niche but durable franchise.
Dojolvi tens of millions in sales, 1 indication
Dojolvi is approved for long-chain fatty acid oxidation disorders, so Ultragenyx Pharmaceutical Inc. has one clear orphan-use revenue stream, not a broad platform. It has an established niche base and limited direct competition, which fits a cash cow profile more than a growth engine. With 1 indication and mature demand, Dojolvi looks like a steady monetization asset for Ultragenyx Pharmaceutical Inc.
Dojolvi low promo spend, steady orphan demand
Dojolvi is an orphan therapy for LC-FAOD, a disorder often cited at about 1 in 50,000 births, so the patient pool is small and well mapped. That lets Ultragenyx keep promo spend contained while repeat use supports steady sales. In 2025, this is classic cash-cow behavior: low growth, but useful cash for R&D.
- Small, defined orphan pool
- Low promo spend, stable demand
- Cash flow can fund other bets
Rare-disease commercial base, cash positive
Ultragenyx Pharmaceutical Inc. has a narrow but durable rare-disease base, so its mature products can act like cash cows once launch costs fade. The model is small in breadth, but it can still support strong margins because niche therapies face limited direct competition and recurring demand. That makes the commercial engine efficient, not broad.
- Small portfolio, steady revenue
- Launch costs already absorbed
- Efficient margins from rare-disease focus
Ultragenyx’s Rare-Disease Cash Cows Keep Funding Growth
Mepsevii and Dojolvi are Ultragenyx Pharmaceutical Inc.'s clearest cash cows: small orphan pools, repeat dosing, and limited direct competition keep sales steady. In 2025, these mature rare-disease brands stayed niche but durable, helping fund broader R&D. Their value is cash generation, not fast growth.
| Product | Cash cow signal |
|---|---|
| Mepsevii | Recurring enzyme use; tiny market |
| Dojolvi | Stable orphan demand; low promo load |
What You See Is What You Get
Ultragenyx Pharmaceutical Inc. Reference Sources
The Ultragenyx Pharmaceutical Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. There are no mockups, watermarks, or demo pages—just the complete, ready-to-use report. Once purchased, the full file is instantly available for download and professional use.
Dogs
Evkeeza limited Ultragenyx footprint, 1 indication
Evkeeza stays a Dog in Ultragenyx Pharmaceutical Inc.’s BCG mix: it has just 1 narrow indication, homozygous familial hypercholesterolemia, a disease affecting roughly 1 in 250,000 to 1,000,000 people. That small pool limits volume, and Ultragenyx’s role is far less central than its core rare-disease franchises, so the asset’s reach and growth stay constrained.
Evkeeza partner-led commercialization, low control
Evkeeza is a partner-led asset, so Ultragenyx does not fully control pricing, rollout, or margin capture. That weakens its ability to build a dominant in-house franchise, and it keeps the product in a lower-control BCG bucket. With annual therapy cost near $450,000, the product is valuable, but partner dependence still caps strategic upside.
Very small HoFH pool, slow expansion
HoFH is ultra-rare, with prevalence estimated at about 1 in 300,000 to 1 in 1,000,000 people, so new-patient flow is thin. Even a differentiated therapy can’t scale fast when the addressable base is this small, and uptake depends on hard-to-find specialist diagnosis. That slow growth and tiny pool fit the Dog profile for Ultragenyx Pharmaceutical Inc.
Non-core commercial tails, low share
Ultragenyx Pharmaceutical Inc.’s non-core commercial tails fit the Dog zone because they appear to make up a low single-digit share of sales and have limited room to scale. These assets can still consume commercial, regulatory, and support time, but they do not change the company’s earnings mix in a material way. In BCG terms, low share plus weak expansion keeps them in Dog territory.
- Low share, limited growth.
- Small revenue contribution.
- Consumes support, not earnings upside.
Residual orphan niches, minimal upside
Ultragenyx Pharmaceutical Inc.'s dog niches are small, rare-disease slots with strong science but limited scale, so they rarely move the top line much. These markets stay fragmented, hard to expand, and often need high trial and support spend for little revenue lift, which weakens the case for heavy capital allocation.
- Small patient pools limit sales upside.
- Fragmentation blocks fast expansion.
- Heavy spend can outstrip returns.
In a BCG Matrix, these programs fit Dogs: useful to keep for clinical value, but not as priority growth engines.
Evkeeza: Tiny Market, Limited Upside for Ultragenyx
Evkeeza remains a Dog for Ultragenyx Pharmaceutical Inc.: homozygous familial hypercholesterolemia affects only about 1 in 250,000 to 1 in 1,000,000 people, so growth is capped by a tiny patient pool. Partner-led control also limits margin capture, and the asset is unlikely to drive material 2025-2026 revenue mix change.
| Metric | Data |
|---|---|
| Indication | HoFH |
| Prevalence | 1 in 250,000 to 1 in 1,000,000 |
| Position | Dog |
Question Marks
DTX401 Phase 3, GSD Ia
DTX401 is a Phase 3 gene therapy for GSD Ia, a rare disease with an estimated prevalence of about 1 in 100,000 births. The market is attractive because patients need life-long management, but Ultragenyx still has zero commercial share here. That is classic Question Mark: high upside if approved, but no revenue yet.
DTX301 Phase 3, OTC deficiency
DTX301 for OTC deficiency sits in the Question Mark box: OTC deficiency is a severe, high-need rare disease, but the asset is still pre-commercial and must prove both efficacy and adoption. In 2025/2026, it has no product revenue, so its current market share is zero while the growth runway could be large if Phase 3 succeeds. That makes it high potential, but still a bet.
GTX-102 Phase 3, Angelman syndrome
Angelman syndrome, at roughly 1 in 12,000 to 20,000 births, is a high-unmet-need orphan market that is much bigger than Ultragenyx Pharmaceutical Inc. current commercial base. GTX-102 is still in Phase 3, so it is not yet a revenue driver. If it succeeds, the program could move from Question Mark to Star, with strong pricing power in a rare disease market.
UX143 Phase 3, osteogenesis imperfecta
UX143 Phase 3 sits in the Question Marks bucket: osteogenesis imperfecta affects about 1 in 15,000 to 20,000 births, so the addressable rare-disease pool is meaningful, but UX143 has no sales yet because it is still in late-stage development. Ultragenyx must fund the program now, with returns only after approval and launch.
- Large rare-disease need
- Phase 3, no market share
- Needs near-term R&D spend
- Upside depends on approval
UX701 and UX053 early-stage, Wilson and GSD III
UX701 and UX053 are early-stage and still have no market presence, so they fit Ultragenyx Pharmaceutical Inc.’s Question Marks bucket. Both target severe rare diseases, which can support high pricing and strong demand if trials work. But until they show clearer clinical data, they remain high-risk, high-upside bets that could move toward Stars or stay niche programs.
- Early-stage, no sales base
- Rare disease upside is large
- Clinical proof will decide status
Ultragenyx’s Rare-Disease Pipeline: Big Upside, Zero 2025 Revenue
Ultragenyx Pharmaceutical Inc.’s Question Marks are its late-stage and early-stage rare-disease programs: DTX401, DTX301, GTX-102, UX143, UX701, and UX053. They target high-need markets with roughly 1 in 100,000 GSD Ia births, 1 in 12,000 to 20,000 Angelman cases, and 1 in 15,000 to 20,000 osteogenesis imperfecta births, but they still have zero 2025 revenue and no market share. The upside is real, but approval risk and launch spend still decide the outcome.
| Program | Status | 2025 Revenue | BCG View |
|---|---|---|---|
| DTX401 | Phase 3 | 0 | Question Mark |
| GTX-102 | Phase 3 | 0 | Question Mark |
| UX143 | Phase 3 | 0 | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.